The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program but also Medicaid and Medicare Part B if manufacturers implement a cash replenishment model, counsel for Eli Lilly—the manufacturer of Mounjaro, Trulicity and other treatments for weight loss or diabetes—alleged in their complaint.

Click Here To Read The Full Article